Company Description
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Feb 6, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 436 |
| CEO | John Evans |
Contact Details
Address: 238 Main Street, 9th Floor Cambridge, Massachusetts 02142-1016 United States | |
| Phone | 857 327 8775 |
| Website | beamtx.com |
Stock Details
| Ticker Symbol | BEAM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0000789073 |
| CUSIP Number | 07373V105 |
| ISIN Number | US07373V1052 |
| Employer ID | 13-3295276 |
| SIC Code | 2080 |
Key Executives
| Name | Position |
|---|---|
| John M. Evans M.B.A. | Chief Executive Officer and Director |
| Dr. Giuseppe Ciaramella Ph.D. | President |
| Dr. Christine P. Bellon J.D., Ph.D. | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. Amy Simon M.D. | Chief Medical Officer |
| Dr. Feng Zhang Ph.D. | Co-Founder |
| Dr. David R. Liu Ph.D. | Co-Founder |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder |
| Bethany J. Cavanagh | Senior Vice President of Finance and Treasurer |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer |
| Dr. Gopi Shanker Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | NO ACT | Filing |
| May 12, 2014 | 15-12B | Securities registration termination |
| May 12, 2014 | 15-12B | Securities registration termination |
| May 2, 2014 | 25 | Filing |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Apr 30, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |